Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has issued an announcement.
On January 28, 2026, OKYO Pharma announced it had held a successful Type C meeting with the U.S. Food and Drug Administration regarding the planned Phase 2b/3 human clinical trial of urcosimod for neuropathic corneal pain. The FDA confirmed that the proposed primary endpoint of Visual Analogue Scale pain reduction at Week 12 is clinically meaningful, endorsed the study design, sample size and powering assumptions, agreed that the Ocular Pain Assessment Survey is appropriate supportive evidence, and aligned on the company’s chemistry, manufacturing and controls strategy without raising material issues—collectively helping to de-risk the path toward a pivotal trial and potential future registration. Urcosimod, which already holds an IND and fast track designation for NCP and has produced positive Phase 2 data, is expected to enter a 120-patient Phase 2b/3 multiple-dose study in the first half of this year, marking a key value-inflection point for OKYO and a potentially important advance in a condition that currently lacks any FDA-approved therapies.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is held down primarily by weak fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) despite improved 2025 cost and cash-burn trends and zero debt. Technicals are a meaningful offset with strong momentum above key moving averages, while valuation remains challenged due to negative earnings and no indicated dividend yield.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, with its ordinary shares traded on the Nasdaq Capital Market. Its flagship product candidate, urcosimod (formerly OK-101), is a chemerin peptide agonist targeting the ChemR23 receptor, and has shown anti-inflammatory and pain-reducing activity in preclinical models and positive outcomes in prior Phase 2 clinical trials for both NCP and dry eye disease.
Average Trading Volume: 174,370
Technical Sentiment Signal: Buy
Current Market Cap: $81.24M
See more data about OKYO stock on TipRanks’ Stock Analysis page.